Biotechnology

Sanctions Covid-19 Mergers and Acquisitions Central Nervous System Disorders Drug Development Research and Development Trade Relations Patient Care Drug Efficacy Cancer Treatment

FDA Approves Regeneron and Sanofi’s Dupixent for Bullous Pemphigoid

The FDA cited ADEPT Phase 2/3 trial data showing sustained remission alongside reduced corticosteroid exposure in elderly patients.

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy

ISSCR Issues Updated Guidelines to Regulate Stem Cell-Based Embryo Models

Engineered Extracellular Vesicles Advance Precision Therapeutic Delivery

Cue Biopharma Finalizes $20 Million Public Offering Ahead of Business Update Call

Biogen Announces Move to New Headquarters in Kendall Common

Cargo Therapeutics Ceases Operations Following Clinical and Financial Setbacks

China Adds PVH and Illumina to 'Unreliable Entity' List